Form 4: NovaBay Pharmaceuticals Director Julie Garlikov Acquires 30,000 Restricted Stock Units

Director Julie Garlikov of NovaBay Pharmaceuticals acquired 30,000 restricted stock units on May 28, 2024, according to a recent SEC filing.

Summary

• On May 28, 2024, Julie Garlikov, a director of NovaBay Pharmaceuticals, acquired 30,000 restricted stock units.
• Each restricted stock unit represents a contingent right to receive one share of NovaBay's common stock.
• The restricted stock units vest on the one-year anniversary of the grant date.
• The filing indicates that Garlikov directly owns these securities.
• The reported number of restricted stock units does not reflect the 1-for-35 reverse stock split that NovaBay implemented on May 30, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard SEC filing reporting the acquisition of restricted stock units by a director. While insider ownership is generally viewed positively, the document itself doesn't convey strong positive or negative signals.

Positives

• The acquisition of restricted stock units by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting of the restricted stock units in one year suggests a time horizon for potential value realization.

Industry Context

Insider transactions are closely watched by investors as they can provide insights into management's perspective on the company's prospects. This Form 4 filing is a routine disclosure required by the SEC.

Stakeholder Impact

• The acquisition of restricted stock units by a director could positively influence shareholder sentiment.

Key Dates

Keywords

NovaBay Pharmaceuticals, Director, Julie Garlikov, Restricted Stock Units, NBY, SEC Form 4, Beneficial Ownership, Vesting, Reverse Stock Split